GSK plc (LSE/NYSE: GSK) today announced the completion of its

葛兰素史克公司（GSK plc，伦敦证券交易所/纽约证券交易所代码：GSK）今天宣布已完成其

previously announced

此前已宣布

acquisition of efimosfermin alfa from Boston Pharmaceuticals. Efimosfermin is a phase III-ready, potential best-in-class investigational specialty medicine aimed at treating and preventing the progression of SLD.

从波士顿制药公司获得Efimosfermin alfa。Efimosfermin是一种处于三期临床准备阶段的潜在最佳研究性专科药物，旨在治疗和预防SLD的进展。

Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), including cirrhosis, and future development in alcohol-related liver disease (ALD), both forms of SLD. Currently, MASH and ALD have limited treatment options and are the leading causes of liver transplant in the US, representing a significant burden and cost on healthcare utilisation..

Efimosfermin 是一种新型的、每月一次的成纤维细胞生长因子 21 (FGF21) 类似物治疗药物，目前正处于临床开发阶段，用于治疗代谢功能障碍相关脂肪性肝炎 (MASH)，包括肝硬化，并计划未来用于酒精相关性肝病 (ALD)，这两种均属于严重肝病 (SLD)。目前，MASH 和 ALD 的治疗选择有限，是美国肝移植的主要原因，对医疗资源利用造成了重大负担和成本。

GSK, based on its work in human genetics and disease phenotyping, believes efimosfermin has potential to address more advanced stages of SLD due to its direct antifibrotic mechanism of action, and sees opportunity in combination with GSK’990, a siRNA therapeutic in development for other subsets of patients with SLD..

基于其在人类遗传学和疾病表型研究方面的工作，GSK认为efimosfermin因其直接的抗纤维化作用机制，有潜力应对SLD更晚期的阶段，并认为与GSK’990（一种正在为其他SLD患者亚群开发的siRNA疗法）联合使用也存在机会。

Kaivan Khavandi, SVP & Global Head, Respiratory, Immunology & Inflammation R&D, GSK

凯万·哈凡迪，高级副总裁兼全球负责人，呼吸、免疫与炎症研发，葛兰素史克

said: “The close of our acquisition for efimosfermin alfa represents a significant expansion of our hepatology pipeline aimed at addressing steatotic and viral drivers of liver disease. Efimosfermin is a key growth opportunity for GSK with multiple development options and potential first launch in 2029.

表示：“收购 efimosfermin alfa 的完成标志着我们针对脂肪变性和病毒性肝病驱动因素的肝病学管线的重大扩展。Efimosfermin 是 GSK 的一个关键增长机会，具有多种开发选择，预计将在 2029 年首次上市。”

We look forward to unlocking the potential of this medicine for patients.” .

我们期待着为患者释放这种药物的潜力。

GSK is driving innovation for a range of immune-mediated conditions by harnessing the science of the immune system and advanced technologies. The addition of efimosfermin further expands GSK's pipeline to address fibro inflammatory diseases in liver, lung and kidney, a key focus for the company.

GSK通过利用免疫系统的科学和先进技术，推动了一系列免疫介导疾病的创新。Efimosfermin的加入进一步扩展了GSK的产品线，以应对肝脏、肺和肾脏的纤维炎症疾病，这是公司的重点之一。

Financial considerations

财务考量

GSK has acquired BP Asset IX, Inc., a subsidiary of Boston Pharmaceuticals, to access efimosfermin. The total cash consideration for this acquisition amounts to up to $2 billion, comprising an upfront payment of $1.2 billion and up to $800 million in success-based milestone payments. GSK will also be responsible for success-based milestone payments as well as tiered royalties for efimosfermin owed to Novartis Pharma AG. .

GSK已收购波士顿制药公司的子公司BP Asset IX, Inc.，以获取efimosfermin。此次收购的总现金对价高达20亿美元，其中包括12亿美元的首付款和高达8亿美元的基于成功的里程碑付款。GSK还将负责向诺华制药公司支付基于成功的里程碑付款以及efimosfermin的阶梯式特许权使用费。

About efimosfermin alfa

关于efimosfermin alfa

Efimosfermin is an investigational, once-monthly subcutaneous injection of a long-acting variant of FGF21 that is designed to regulate key metabolic pathways to decrease liver fat, ameliorate liver inflammation, and reverse liver fibrosis in patients with MASH. Efimosfermin is currently in trials for moderate to advanced fibrosis, including cirrhosis and is not approved anywhere in the world..

Efimosfermin 是一种研究性药物，每月一次皮下注射的长效 FGF21 变体，旨在调节关键代谢途径，以减少肝脏脂肪、改善肝脏炎症，并逆转 MASH 患者的肝纤维化。Efimosfermin 目前正在进行中度至重度纤维化（包括肝硬化）的试验，尚未在全球任何地方获批。

About Boston Pharmaceuticals

关于波士顿制药公司

Boston Pharmaceuticals is a clinical-stage biopharmaceutical company that leverages an experienced and committed drug development team to advance a portfolio of highly differentiated therapies that may address important unmet medical needs in serious liver diseases. Boston Pharmaceuticals is a portfolio company of B-Flexion, a private, entrepreneurial investment firm which manages the combined funds and investments associated with the Bertarelli family and also partners with sophisticated capital to meet the shared goal of delivering exceptional value over the generations, while also contributing positively to society. .

Boston Pharmaceuticals是一家临床阶段的生物制药公司，利用经验丰富且专注的药物开发团队，推进一系列高度差异化的疗法，这些疗法可能满足严重肝病领域重要的未满足医疗需求。Boston Pharmaceuticals是B-Flexion的投资组合公司，B-Flexion是一家私营的创业投资公司，管理与Bertarelli家族相关的综合基金和投资，同时与精明的资本合作，以实现跨代创造卓越价值的共同目标，并为社会做出积极贡献。

About GSK research in hepatology

关于GSK在肝病学领域的研究

GSK is currently investigating multiple potential treatments for patients with liver disease, including treatments for chronic hepatitis B, alcohol-related liver disease (ALD), and metabolic dysfunction-associated steatohepatitis (MASH).

GSK目前正在研究多种针对肝病患者的潜在治疗方法，包括慢性乙型肝炎、酒精相关性肝病（ALD）以及代谢功能障碍相关的脂肪性肝炎（MASH）的治疗方案。

About GSK

关于GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

GSK是一家全球生物制药公司，致力于联合科学、技术和人才，共同战胜疾病。欲了解更多信息，请访问gsk.com。